Working PaperArticleVersion 1This version is not peer-reviewed
The Rationale for a Multi-Step Therapeutic Approach Based On Antivirals and Drugs with Immunomodulatory Activity in Patients With Coronavirus-Sars2-Induced Disease of Different Severity
Version 1
: Received: 21 April 2020 / Approved: 23 April 2020 / Online: 23 April 2020 (05:44:52 CEST)
How to cite:
Fiorino, S.; Zippi, M.; Gallo, C.; Sifo, D.; Sabbatani, S.; Manfredi, R.; Rasciti, E.; Rasciti, L.; Giampieri, E.; Corazza, I.; Leandri, P.; de Biase, D. The Rationale for a Multi-Step Therapeutic Approach Based On Antivirals and Drugs with Immunomodulatory Activity in Patients With Coronavirus-Sars2-Induced Disease of Different Severity. Preprints2020, 2020040406
Fiorino, S.; Zippi, M.; Gallo, C.; Sifo, D.; Sabbatani, S.; Manfredi, R.; Rasciti, E.; Rasciti, L.; Giampieri, E.; Corazza, I.; Leandri, P.; de Biase, D. The Rationale for a Multi-Step Therapeutic Approach Based On Antivirals and Drugs with Immunomodulatory Activity in Patients With Coronavirus-Sars2-Induced Disease of Different Severity. Preprints 2020, 2020040406
Fiorino, S.; Zippi, M.; Gallo, C.; Sifo, D.; Sabbatani, S.; Manfredi, R.; Rasciti, E.; Rasciti, L.; Giampieri, E.; Corazza, I.; Leandri, P.; de Biase, D. The Rationale for a Multi-Step Therapeutic Approach Based On Antivirals and Drugs with Immunomodulatory Activity in Patients With Coronavirus-Sars2-Induced Disease of Different Severity. Preprints2020, 2020040406
APA Style
Fiorino, S., Zippi, M., Gallo, C., Sifo, D., Sabbatani, S., Manfredi, R., Rasciti, E., Rasciti, L., Giampieri, E., Corazza, I., Leandri, P., & de Biase, D. (2020). The Rationale for a Multi-Step Therapeutic Approach Based On Antivirals and Drugs with Immunomodulatory Activity in Patients With Coronavirus-Sars2-Induced Disease of Different Severity. Preprints. https://doi.org/
Chicago/Turabian Style
Fiorino, S., Paolo Leandri and Dario de Biase. 2020 "The Rationale for a Multi-Step Therapeutic Approach Based On Antivirals and Drugs with Immunomodulatory Activity in Patients With Coronavirus-Sars2-Induced Disease of Different Severity" Preprints. https://doi.org/
Abstract
In December 2019 a novel human-infecting coronavirus, named SARS-CoV-2 has been recognized to cause a pneumonia epidemic outbreak with different degree of severity in Wuhan, Hubei Province in China. Since then this epidemic spread worldwide an in the last week Europe and Italy also have been involved. Effective preventive and therapeutic strategies are absolutely required to block this serious public health concern. Unfortunately, SARS-CoV-2 has been isolated only recently, therefore a few studies concerning its immunopathogenesis and tretament are available. Therefore, on the basis of the assumption that the SARS-CoV-2 is genetically related to SARS-CoV (about 82% of genome homology) and that its characteristics, like the modality of transmission, the route of infection, the organ localization, the type of the immune response it may stimulate, the morbidity and the mortality rates are still poor-known, a literature search was performed to identify the reports assessing these elements in patients with SARS-CoV-induced infection. Therefore, we have analysed:1) the structure of SARS CoV-2 and SARS CoV;2) the clinical signs and symptoms and pathogenic mechanisms observed during the development of acute respiratory syndrome and the Cytokine Release Syndrome;3) the modification of the cell microRNome and of the immune response in patients with SARS infection;4) the possible role of some liposoluble compounds (such as vitamin A, D and E) in modulating directly or indirectly the replication ability of SARS-CoV-2 and host immune response.
Keywords
SARS; Covid-19; Vitamins; Therapy
Subject
Medicine and Pharmacology, Pathology and Pathobiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
